Trials / Completed
CompletedNCT01797536
The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009)
A Three-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-8742
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) profile of elbasvir (MK-8742) after a single dose to participants with mild, moderate, or severe hepatic insufficiency compared with healthy controls.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Elbasvir |
Timeline
- Start date
- 2013-03-06
- Primary completion
- 2014-08-20
- Completion
- 2014-08-20
- First posted
- 2013-02-22
- Last updated
- 2018-10-25
- Results posted
- 2016-11-18
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01797536. Inclusion in this directory is not an endorsement.